During Tuesday’s Current trade, Shares of Fairchild Semiconductor Intl Inc (NASDAQ:FCS), lost -3.24% to $13.43.
Fairchild (FCS), a leading global supplier of power semiconductors, updated its guidance range for the third quarter of 2015. Fairchild now anticipates third quarter sales to be about $340 million contrast to the previous range of $355 to $375 million. Adjusted gross margin is predictable to be within the previous guidance range of 34.0 to 35.0 percent. Operating expenses are now forecast to be $90 to $92 million contrast to the previous guidance of $95 to $97 million.
Fairchild also declared it has initiated a program to structurally reduce operating expenses by about $30 to $34 million annually which is predictable to be implemented by the middle of the fourth quarter of 2015. This is a structural change to the operating expense level of the company and the anticipated savings contain no temporary measures. The company anticipates to incur about $13 million of severance expenses in the third quarter associated with this program.
Fairchild Semiconductor International, Inc. designs, develops, manufactures, and markets power analog, power discrete, and non-power semiconductor solutions worldwide. It operates through three segments: Mobile, Computing, Consumer, and Communication (MCCC); Power Conversion, Industrial, and Automotive (PCIA); and Standard Discrete and Standard Linear (SDT). The MCCC segment offers analog components, mixed signal integrated circuits (ICs), and low voltage power metal oxide semiconductor field effect transistors (MOSFETs) for mobile, consumer, computing, and communication applications; signal path products, such as analog and digital switches, USB switches, video filters, and audio amplifiers; and packaging solutions comprise surface mount devices, tiny packages, chip scale packages, and leadless carriers.
Shares of Neurocrine Biosciences, Inc.(NASDAQ:NBIX), declined -3.47% to $48.44, during its current trading session.
AbbVie (ABBV), in cooperation with Neurocrine Biosciences, Inc. (NBIX), declared the completion of a Phase 2b clinical trial evaluating the safety and efficacy of elagolix alone or in combination with add-back therapy contrast to placebo. The trial was conducted in women with heavy menstrual bleeding (HMB) associated with uterine fibroids. Preliminary results showed that all of the elagolix treatment arms, with and without add-back therapy, reduced heavy menstrual bleeding as contrast to placebo (p
Uterine fibroids (also called leiomyomas or myomas) are noncancerous muscle tissue tumors of the uterus.1 Fibroids are most common in women aged 30-40 years but can occur at any age.1 They can range in size from nearly undetectable to bulky masses that can distort the uterus.2 Fibroids can be asymptomatic but in some women cause symptoms such as: longer, more frequent, or heavy menstrual bleeding; menstrual pain; vaginal bleeding at time other than menstruation; pain in the abdomen or lower back; pain during sex; difficulty urinating; frequent urination; constipation or rectal pain.
Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company’s products in clinical development stage comprise elagolix, which is in Phase III study for endometriosis; elagolix that is in Phase IIb study for uterine fibroids; Corticotropin-Releasing Factor Receptor1 Antagonist, which is in Phase I/II study for congenital adrenal hyperplasia and stress-related disorders; and Vesicular Monoamine Transporter 2 Inhibitor (VMAT2) that is in Phase III study for movement disorders, in addition to Phase I study for tourette syndrome.
Workday Inc (NYSE:WDAY), during its Tuesday’s current trading session decreased -1.09% to $72.37.
Workday, Inc. (WDAY), a leader in enterprise cloud applications for finance and human resources, declared that it will host its financial analyst day on Tuesday, Sept. 29, 2015 in Las Vegas at 2:30 p.m. Pacific Time / 5:30 p.m. Eastern Time. The event will take place during Workday Rising 2015.
Workday, Inc. provides enterprise cloud applications for finance and human resources in the United States and internationally. It offers applications for customers to manage critical business functions that enable them to optimize their financial and human capital resources.
Finally, Memorial Resource Development Corp (NASDAQ:MRD), decreased -2.00%, to $18.17.
Memorial Resource Development Corp. (MRD) declared that it has priced an underwritten public offering of 12,000,000 shares of its common stock at a price to the public of $17.60 per share. The offering was upsized to 12,000,000 shares of common stock from the original offering size of 10,250,000 shares of common stock. MRD has granted the underwriter an option to purchase up to 1,800,000 additional shares of common stock. MRD intends to use the net proceeds from this offering, and any proceeds from the exercise of the underwriter’s option to purchase additional shares, to fund a portion of the purchase price of MRD’s recently declared pending acquisition of producing and non-producing properties in North Louisiana. If MRD does not complete the pending acquisition, it will use the net proceeds from the offering for general corporate purposes, which may comprise repayment of a portion of the outstanding borrowings under MRD’s senior secured revolving credit facility.
Memorial Resource Development Corp., an independent natural gas and oil company, focuses on the acquisition, exploitation, and development of natural gas, natural gas liquids, and oil properties primarily in North Louisiana. As of December 31, 2014, the company held leasehold interest in 210,854 net acres; and had estimated proved reserves of about 1,632 billion cubic feet of natural gas equivalent.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
